## 2309010035 - ORGANIC **ACIDS DEMO**

**FINAL REPORT** 

Accession ID: 2309010035

Name: 2309010035 - ORGANIC

ACIDS DEMO

Date of Birth: 01-01-1111

Gender: Male Age: 01

Height: 72 inches Weight: 170 lbs Fasting: FASTING Telephone: 000-000-0000

Street Address:

Email:

#### **Provider Information**

Practice Name: DEMO CLIENT, MD Provider Name: DEMO CLIENT, MD

Phlebotomist: 0

Telephone: 000-000-0000 Address: 3521 Leonard Ct, Santa

Clara, CA 95054

#### **Report Information**

Current Result Previous Result

In Control Moderate Risk

### **Specimen Information**

Sample Type	Collection Time	Received Time	Report	Final Report Date
Metal Free Urine	2023-09-11 16:45 (PDT)	2023-09-13 15:40 (PDT)	Organic Acids - P2	2023-09-27 11:19 (PDT)





Date of Birth: 01-01-1111 Accession ID: 2309010035

Service Date: 2023-09-11 16:45 (PDT)

## **Organic Acids**

#### INTRODUCTION

Vibrant Wellness is pleased to present to you, 'Organic acids', to help you make healthy lifestyle, dietary and treatment choices in consultation with your healthcare provider. It is intended to be used as a tool to encourage a general state of health and well-being. Vibrant Organic acids is a test to identify and quantify the level of a large set of organic acids from urine. This panel is designed to provide a comprehensive assessment of metabolism products including evaluation of intestinal microbial overgrowth, detoxification, mitochondrial markers, neurotransmitter metabolism, glutathione status, fatty acid metabolism, inborn errors of metabolism.

#### Methodology:

The Vibrant Organic Acids panel uses Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS) for quantitative detection of organic acids in urine samples. Additionally, catecholamine metabolites and serotonin & kynurenine metabolites are measured using tandem mass spectrometry methodology (LC-MS/MS). Urine creatinine is measured using a kinetic colorimetric assay based on the Jaffé method. All Organic acids are reported as the quantitative result normalized to urine creatinine to account for urine dilution variations.

#### **Interpretation of Report:**

The report begins with the summary page which lists only the organic acids whose levels are outside the normal reference range. Reference ranges have been established using a cohort of 1000 apparently healthy individuals. Following this section is a graphical representation of the AXON terminal and a summary of Krebs cycle including the results for the relevant analytes. This is followed by a complete list of the organic acids which are represented normalized to urinary creatinine, in a bar graph form to enable a full overview along with the reference ranges. The level of the organic acid has a green (normal) or red (high/low) highlight around the cell indicating the corresponding result based on the reference range of each organic acid. Additionally, the previous value (if available) is also indicated to help check for improvements every time the test is ordered.

The Vibrant Wellness platform provides tools for you to track and analyze your general wellness profile. Testing for the Organic acids panel is performed by Vibrant America, a CLIA certified lab CLIA#:05D2078809. Vibrant Wellness provides and makes available this report and any related services pursuant to the Terms of Use Agreement (the "Terms") on its website atwww.vibrant-wellness.com. By accessing, browsing, or otherwise using the report or website or any services, you acknowledge that you have read, understood, and agree to be bound by these terms. If you do not agree to these terms, you shall not access, browse, or use the report or website. The statements in this report have not been evaluated by the Food and Drug Administration and are only meant to be lifestyle choices for potential risk mitigation. Please consult your healthcare provider for medication, treatment, or lifestyle management. This product is not intended to diagnose, treat, or cure any disease.

#### Please note:

Pediatric ranges have not been established for this test. It is important that you discuss any modifications to your diet, exercise, and nutritional supplementation with your healthcare provider before making any changes.





Date of Birth: 01-01-1111 Accession ID: 2309010035

Service Date: 2023-09-11 16:45 (PDT)

## Organic Acids - Summary



The metabolite 2-hydroxyisovaleric acid is mainly formed from ketogenesis and metabolism of valine, leucine, and isoleucine[vi]. Urinary 2-hydroxyisovaleric acid is associated with lactic acidosis and ketoacidosis. Additionally, chronically high levels of 2-hydroxyisovaleric acid are found in the urine of patients with phenylketonuria, methylmalonic acidemia, propionic acidemia, 3-ketothiolase deficiency, isovaleric acidemia, 3-hydroxy-3-methylglutaric acidemia, multiple carboxylase deficiency, glutaric acidemia, ornithine transcarbamylase deficiency, glyceroluria, tyrosinemia type I, galactosemia, and maple syrup urine disease.



Homogentisic acid is an intermediate in the breakdown or catabolism of tyrosine and phenylalanine. Chronically high levels of homogentisic acid are associated with alkaptonuria, a rare inborn error of metabolism in which the body cannot process the amino acids phenylalanine and tyrosine. Slight increases may indicate the heterozygous genetic carrier state of the disease. The accumulating homogentisic acid may cause damage to cartilage and heart valves as well as precipitate kidney stones and stones in other organs. Vitamin C may exacerbate Alkaptonuria[ix]



N-Acetylaspartic acid is a derivative of aspartic acid. It is the second most concentrated molecule in the brain and is synthesized in neurons from the amino acid aspartate and acetyl coenzyme A (acetyl CoA). N-Acetylaspartic acid is believed to be involved in many physiological functions in the brain. High levels of urine N-acetylaspartic acid are associated with an autosomal recessive genetic condition called Canavan disease. Severe cases of this condition give rise to clinical presentations that include macrocephaly, poor head control, seizures, abnormal muscle tone, optic atrophy, significant developmental delay, and death. N-Acetylaspartic acid can also be elevated in HPV infections[x]. Certain cancers, such as non-small cell lung cancer also showed elevated levels of N-Acetylaspartic acid[xi].

#### **Detoxification & Oxidative Stress**

No markers are outside the normal reference range



4-Hydroxybutyric acid (also known as gamma-hydroxybutyrate or GHB) is a precursor and a metabolite of gamma-aminobutyric acid (GABA). GHB acts as a central nervous system (CNS) neuromodulator, mediating its effects through GABA and GHB-specific receptors, or by affecting dopamine transmission. Elevated urinary levels of 4-hydroxybutyric acid can be caused by the genetic disorder involving succinic semialdehyde dehydrogenase deficiency.



Date of Birth: 01-01-1111 Accession ID: 2309010035

Service Date: 2023-09-11 16:45 (PDT)

## Organic Acids - Summary



Arabinose is produced by the action of Candida hyaluronidase on the intercellular cement hyaluronic acid. The oxidative products of hyaluronic acid breakdown include arabinose as well as tartaric acid. Arabinose has been found elevated in urine of autistic males and reduced after nystatin therapy. Arabinose is also a major sugar in apples, grapes, and pears, therefore, it's recommended to avoid these foods prior to collecting a sample for the organic acids test. Correlation of candida with clinical symptoms can vary depending on individual sensitivity, total microbial burden, function of glutathione system, acetaldehyde dehydrogenase, general nutritional status and functional health of the individual. Follow-up testing with gut zoomer and fungal antibodies can help further determine root cause. Comprehensive gastrointestinal protocols may be recommended, to include anti-fungals (herbal or prescription), high potency probiotics, detox support and intestinal lining support.

# Neurotransmitters & Stress Hormones Catecholamine Metabolites & Current Previous Result Reference HVA/DOPAC Ratio 8.47

A low ratio indicates a higher level of DOPAC compared to HVA. Factors that contribute to a low ratio include slowed COMT activity, impaired methylation, magnesium deficiency and heavy metal toxicity. A high ratio indicates a higher level of HVA compared to DOPAC. Factors that contribute to a high ratio include increased methylation and any other factors that may induce COMT activity, such as genetic SNPs, medications, supplements, can also result in a higher ratio.

Serotonin & Kynurenine Metabolites & Ratios	Current	Previous		Result	Reference
Quinolinic acid/5-HIAA Ratio	0.12		0 0.31	1.1	0.32-1.1

Quinolinic acid is a neuroactive product of the kynurenine pathway. Quinolinic acid acts as an NMDA receptor agonist and effectively inhibits reuptake of glutamate by astrocytes, contributing to excitotoxicity. Quinolinic acid has multiple neurotoxic impacts on the body, including production of reactive oxygen species, disruption of the blood brain barrier, destabilization of the cellular cytoskeleton, promotion of tau phosphorylation, impaired autophagy and enhanced inflammatory response from proinflammatory mediators in astrocytes. Under certain conditions such as stress or inflammation, L-tryptophan is shunted way from the serotonin pathway and towards the kynurenine pathway, which forms quinolinic acid and then synthesizes NAD+ as the end product.

#### **Nutrition & Oxalates**

No markers are outside the normal reference range

Creatinine				
Urine Creatinine	Current	Previous	Result	Reference
Urine Creatinine (mg/ml)	1.87		0 0.24 2.16	0.25-2.16




Date of Birth: 01-01-1111 Accession ID: 2309010035

Service Date: 2023-09-11 16:45 (PDT)


## Organic Acids - Summary

#### **AXON Terminal**

#### Tryptophan metabolites & ratios



#### **Catecholamine Metabolites & Ratios**




Legend Hig	gh/Low Moderate	In contr	rol • Current Value		nation and cortisol are inducers of the ine pathway
ABBREVIA 5-HTP 5-HIAA COMT DOPAC	5-hydroxytryptophan 5-hydroxyindoleacetic acid Catechol-O-methyltransferase 3,4-dihydroxyphenylacetic acid		Homovanillic acid Indoleamine 2,3-dioxygenase Kynurenine aminotransferase L-3,4-dihydroxyphenylalanine	MAO TDO VMA DBH	Monoamine oxidase Tryptophan-2,3-dioxygenase Vanillylmandelic acid Dopamine Beta Hydroxylase

Date of Birth: 01-01-1111 Accession ID: 2309010035

Service Date: 2023-09-11 16:45 (PDT)

## Organic Acids - Summary





Date of Birth: 01-01-1111 Accession ID: 2309010035

Service Date: 2023-09-11 16:45 (PDT)

Amino Acid Metabolites				
Amino Acid Metabolites	Current	Previous	Result	Reference
2-Hydroxyisocaproic acid (mmol/mol)	0.77		0 0.88	≤0.88
2-Hydroxyisovaleric acid (mmol/mol)	1.55		0 0.4	≤0.4
2-Oxo-4-methiolbutyric acid (mmol/mol)	0.06		0 0.18	≤0.18
2-Oxoisocaproic acid (mmol/mol)	0.30		0 0.41	≤0.41
2-Oxoisovaleric (mmol/mol)	1.89		0 2	≤2.0
3-Methyl-2-oxovaleric acid (mmol/mol)	0.47		0 2.6	≤2.6
4-Hydroxyphenyllactic acid (mmol/mol)	0.29		0 0.84	≤0.84
Homogentisic acid (mmol/mol)	1.09		0 0.35	≤0.35
Malonic acid (mmol/mol)	0.91		0 9.8	≤9.8
N-Acetylaspartic acid (mmol/mol)	10.21		0 3.9	≤3.9
Phenyllactic acid (mmol/mol)	0.16		0 0.21	≤0.21
Phenylpyruvic acid (mmol/mol)	1.98		0 0.22 2.2	0.23-2.2
Detoxification & Oxidative	Stress			
Ammonia	Current	Previous	Result	Referenc
Orotic acid (mmol/mol)	0.22		0 0.07 0.52	0.08-0.52
Glutathione	Current	Previous	Result	Reference
N-Acetylcystei <mark>ne acid</mark> (mmol/mol)	0.18		0 0.26	≤0.26
N-Acetylcystei <mark>ne acid</mark> (mmol/mol) Pyroglutamic acid (mmol/mol)	0.18 25.98		0 0.26	
(mmol/mol)		Previous	•	10.14-32.4
(mmol/mol)  Pyroglutamic acid (mmol/mol)	25.98	Previous	0 10.1 32.4  Result	10.14-32.
(mmol/mol)  Pyroglutamic acid (mmol/mol)  Oxidative Stress  2-Hydroxybutyric acid	25.98 Current	Previous Previous	0 10.1 32.4  Result	≤0.26  10.14-32.4  Reference  0.06-1.56  Reference

Date of Birth: 01-01-1111 Accession ID: 2309010035

Service Date: 2023-09-11 16:45 (PDT)

Metabolism & Mitochondri	al Function			
Amino Acid Metabolites	Current	Previous	Result	Reference
4-Hydroxybutyric acid (mmol/mol)	17.16		0 4.57	≤4.57
Fat & Ketones	Current	Previous	Result	Reference
3-Hydroxybutyric acid (mmol/mol)	2.01		0 3.5	≤3.5
Acetoacetic acid (mmol/mol)	7.00		0 9.6	≤9.6
Adipic acid (mmol/mol)	3.16		0 0.03 3.9	0.04-3.9
Ethylmalonic acid (mmol/mol)	2.09		0 0.46 2.74	0.47-2.74
Methylsuccinic acid (mmol/mol)	0.33		0 0.12 2.14	0.13-2.14
Sebacic acid (mmol/mol)	0.10		0 0.23	≤0.23
Suberic acid (mmol/mol)	0.68		0 0.15 2.18	0.16-2.18
Glycolysis	Current	Previous	Result	Referenc
Lactic acid (mmol/mol)	32.39		0 50.4	≤50.4
Pyruvic acid (mmol/mol)	3.60		0 9.4	≤9.4
Kreb's Cycle	Current	Previous	Result	Reference
Citric acid (mmol/mol)	421.62		0 498	≤498.8
Cis-aconitic acid (mmol/mol)	23.51		0 6.09 27.9	6.1-27.9
Alpha-ketoglutarate (mmol/mol)	7.89		0 34.7	≤34.77
Succinic acid (mmol/mol)	2.44		0 9.4	≤9.4
Fumaric acid (mmol/mol)	0.58		0 0.91	≤0.91
Malic acid (mmol/mol)	1.52		0 0.07 1.74	0.08-1.74
Mitochondrial Function	Current	Previous	Result	Referenc
3-Hydroxyglutaric acid (mmol/mol)	0.82		0 4.9	≤4.9
3-Methylglutaconic (mmol/mol)	2.31		0 6.2	≤6.2
3-Methylglutaric acid (mmol/mol)	0.42		•	≤0.75

Date of Birth: 01-01-1111 Accession ID: 2309010035

Service Date: 2023-09-11 16:45 (PDT)



Date of Birth: 01-01-1111 Accession ID: 2309010035

Service Date: 2023-09-11 16:45 (PDT)

Service Date: 2023-09-11 16:45 (PDT)				
Neurotransmitters & Stre	ss Hormones			
Catecholamine Metabolites & Ratios	Current	Previous	Result	Reference
Homovanillic acid (HVA) (mcg/g)	5092.12		0 3534 8455	3535.0- 8455.0
Vanillylmandelic acid (VMA) (mcg/g)	3821.61		0 2411 5047	2411.2- 5047.8
HVA/DOPAC Ratio	8.47		0 2.59 8.3	2.6-8.3
HVA/VMA Ratio	1.33		0 0.73 1.88	0.74-1.88
Serotonin & Kynurenine Metabolites & Ratios	Current	Previous	Result	Reference
5-Hydroxyindoleacetic acid (5- HIAA) (mcg/g)	7254.91		0 1710 9788	1711.0- 9788.0
Kynurenic acid (mcg/g)	177.98		0 125 991	125.6-991.3
Quinolinic acid (mcg/g)	892.06		0 610 2432	610.3-2432.9
Quinolinic acid/5-HIAA Ratio	0.12		0 0.31 1.1	0.32-1.1
Nutrition & Oxalates				
Nutrients	Current	Previous	Result	Reference
3-Hydroxy-3-methylglutaric (mmol/mol)	23.21		0 0.13 38.9	0.14-38.95
Ascorbic acid (Vitamin C) (mmol/mol)	156.96		0 12.1 179	12.2-179.25
Glutaric acid (Vitamin B2) (mmol/mol)	0.16		0 0.02 0.38	0.03-0.38
Methylcitric acid (Biotin) (mmol/mol)	0.83		0 0.14 2.96	0.15-2.96
Methylmalonic acid (Vitamin B12) (mmol/mol)	1.51		0 2.21	≤2.21
Pantothenic acid (Vitamin B5) (mmol/mol)	4.72		0 9.91	≤9.91
Pyridoxic acid (Vitamin B6) (mmol/mol)	23.04		0 34	≤34.0
Phosphoric acid (mmol/mol)	2732		0 999 5000	1000.0- 5000.0
Oxalates	Current	Previous	Result	Reference
Glyceric acid (mmol/mol)	5.93		0 0.73 7.4	0.74-7.4
Glycolic acid (mmol/mol)	72.50		0 12.5 128	12.6-128.7
Oxalic acid (mmol/mol)	26.84		0 6.16 110	6.17-110.52

Date of Birth: 01-01-1111 Accession ID: 2309010035

Service Date: 2023-09-11 16:45 (PDT)

Nutrition & Oxalates				
Pyrimidines	Current	Previous	Result	Reference
Thymine (mmol/mol)	0.33		0 0.63	≤0.63
Uracil (mmol/mol)	8.35		0 9.4	≤9.4
Salicylates	Current	Previous	Result	Reference
2-Hydroxyhippuric acid (mmol/mol)	1.20		0 1.42	≤1.42



Date of Birth: 01-01-1111 Accession ID: 2309010035

Service Date: 2023-09-11 16:45 (PDT)

## **Organic Acids**

#### **Risk and Limitations**

This test has been developed and its performance characteristics determined and validated by Vibrant America LLC., a CLIA certified lab. These assays have not been cleared or approved by the U.S. Food and Drug Administration. Vibrant Wellness provides additional contextual information on these tests and provides the report in more descriptive fashion.

Organic acids panel does not demonstrate absolute positive and negative predictive values for any condition. Its clinical utility has not been fully established. Clinical history and current symptoms of the individual must be considered by the healthcare provider prior to any interventions. Test results should be used as one component of a healthcare provider's clinical assessment.

Organic acids panel testing is performed at Vibrant America, a CLIA certified laboratory. Vibrant America has effective procedures in place to protect against technical and operational problems. However, such problems may still occur. Examples include failure to obtain the result for a specific test due to circumstances beyond Vibrant's control. Vibrant may re-test a sample to obtain these results but upon re-testing the results may still not be obtained. As with all medical laboratory testing, there is a small chance that the laboratory could report incorrect results. A tested individual may wish to pursue further testing to verify any results.

The information in this report is intended for educational purposes only. While every attempt has been made to provide current and accurate information, neither the author nor the publisher can be held accountable for any errors or omissions. Tested individuals may find their experience is not consistent with Vibrant's selected peer reviewed scientific research findings of relative improvement for study groups. The science in this area is still developing and many personal health factors affect diet and health. Since subjects in the scientific studies referenced in this report may have had personal health and other factors different from those of tested individuals, results from these studies may not be representative of the results experienced by tested individuals. Further, some recommendations may or may not be attainable, depending on the tested individual's physical ability or other personal health factors. A limitation of this testing is that many of these scientific studies may have been performed in selected populations only. The interpretations and recommendations are done in the context of these studies, but the results may or may not be relevant to tested individuals of different or mixed ethnicities.

Vibrant Wellness makes no claims as to the diagnostic or therapeutic use of its tests or other informational materials. Vibrant Wellness reports and other information do not constitute medical advice and are not a substitute for professional medical advice. Please consult your healthcare practitioner for questions regarding test results, or before beginning any course of medication, supplementation, or dietary changes.



